Lower Drug Costs Today Act
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Lower Drug Costs Today Act (H.R. 5924) is a health policy bill introduced in the 118th Congress aimed at addressing the cost of prescription drugs. The bill was referred to the House Subcommittee on Health but did not advance further and is currently classified as failed or expired. No official summary or full text is available, limiting detailed analysis of its provisions. The bill's focus on drug costs places it within ongoing legislative efforts to manage healthcare expenses in the United States.
H.R. 5924 sought to lower prescription drug costs but did not progress beyond subcommittee referral and is now expired, with limited publicly available details on its specific measures.
- The bill is titled 'Lower Drug Costs Today Act' and relates to health policy.
- It was introduced in the House during the 118th Congress and referred to the Subcommittee on Health.
- The bill status is failed/expired, indicating it did not pass or advance in the legislative process.
['Patients and consumers seeking lower prescription drug prices', 'Healthcare providers and health systems potentially affected by drug pricing', 'Pharmaceutical industry stakeholders subject to pricing regulations']
['Lack of available full text and official summary limits understanding of implementation details and authority granted', 'Potential costs and funding mechanisms for drug price reductions are unspecified', 'Oversight and enforcement provisions are unknown due to missing bill text', 'Tradeoffs between drug pricing controls and pharmaceutical innovation or market dynamics cannot be assessed']
The bill was introduced in the House during the 118th Congress and referred to the Subcommittee on Health on December 17, 2024. It did not advance beyond this stage and is now classified as failed or expired. This reflects the legislative process where many bills do not progress beyond initial committee consideration. The focus on drug costs aligns with ongoing national debates about healthcare affordability.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential influence on pharmaceutical market pricing strategies if enacted', 'Possible impact on healthcare insurance costs related to prescription drugs', 'Effects on innovation incentives within the pharmaceutical industry depending on pricing controls']
The absence of an official summary and full bill text significantly limits transparency and public understanding of the bill's provisions and potential impacts. This lack of documentation hinders effective oversight and informed debate. Future legislative efforts would benefit from ensuring full and timely publication of bill texts and summaries to support government transparency.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.